Obseva Logo highresolution.jpg
ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways
September 01, 2015 03:00 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 01 September 2015 -...
Obseva Logo highresolution.jpg
ObsEva annonce le recrutement de la première patiente dans TERM, son étude de Phase 2
June 23, 2015 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Une évaluation de l'innocuité et...
Obseva Logo highresolution.jpg
ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study
June 23, 2015 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - Clinical Trial to Evaluate the...
Obseva Logo highresolution.jpg
ObsEva annonce le démarrage d'une étude pivot de Phase 2 portant sur l'évaluation de OBE001 pour améliorer le taux d'implantation d'embryon et de grossesses lors d'une FIV/ICSI
November 18, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Genève, Suisse, 18 novembre 2014 - ObsEva, une...
Obseva Logo highresolution.jpg
ObsEva Announces the Initiation of a Pivotal Phase 2 Study to Evaluate OBE001 for Improving Embryo Implantation and Clinical Pregnancy Rate in Women Undergoing IVF/ICSI
November 18, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 18 November 2014 - ObsEva,...
Obseva Logo highresolution.jpg
ObsEva SA annonce la nomination de Ben T.G. Tan au poste de Vice-Président Commercial & Business Development
September 10, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Genève, Suisse, 10 septembre 2014 - ObsEva, une...
Obseva Logo highresolution.jpg
ObsEva SA appoints Ben T.G. Tan as VP Commercial & Business Development
September 10, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 10 September 2014 -...
Obseva Logo highresolution.jpg
ObsEva SA annonce l'obtention du statut JEDI et du statut européen de SME
July 23, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Genève, Suisse, 23 juillet 2014 -...
Obseva Logo highresolution.jpg
ObsEva SA announced today it was granted JEDI status and European SME status
July 23, 2014 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 23 July 2014 -...
Obseva Logo highresolution.jpg
ObsEva SA announces CHF 32 Million Series A funding from leading Venture Capital firms and a license agreement with Merck Serono
August 29, 2013 02:30 ET | ObsEva SA
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland, 29 August 2013 - ObsEva...